2seventy bio, Inc. (TSVT)
- Previous Close
4.2700 - Open
4.0000 - Bid 4.0700 x 100
- Ask 4.1500 x 300
- Day's Range
3.4400 - 4.1100 - 52 Week Range
1.5350 - 12.6900 - Volume
3,306,958 - Avg. Volume
1,439,891 - Market Cap (intraday)
210.889M - Beta (5Y Monthly) 1.85
- PE Ratio (TTM)
-- - EPS (TTM)
-4.4200 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
www.2seventybio.comRecent News: TSVT
Performance Overview: TSVT
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSVT
Valuation Measures
Market Cap
219.10M
Enterprise Value
258.78M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.10
Price/Book (mrq)
0.86
Enterprise Value/Revenue
2.58
Enterprise Value/EBITDA
-1.25
Financial Highlights
Profitability and Income Statement
Profit Margin
-216.73%
Return on Assets (ttm)
-22.17%
Return on Equity (ttm)
-76.91%
Revenue (ttm)
100.39M
Net Income Avi to Common (ttm)
-217.57M
Diluted EPS (ttm)
-4.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
216.99M
Total Debt/Equity (mrq)
100.54%
Levered Free Cash Flow (ttm)
-114.54M